SciFi Futures
← Concepts
AI & Robotics

AI cybrid (AI persona in a grown human body)

A human body grown from a person's DNA and driven remotely by an AI that has reconstructed that person's personality.

In shortAI cybrid (AI persona in a grown human body), from Hyperion (Dan Simmons, 1989), is at technology readiness level 2 of 9 (technology concept formulated) at its weakest link. Held back by Full-term ectogenesis. Science status: consistent with known physics; key effects unproven at scale. Estimated new funding to unlock: $625B–3.6T.

In Brawne Lamia's tale, her client and lover Johnny is a cybrid, a reconstruction of the poet John Keats running in the TechnoCore and inhabiting a body cloned from Keats's DNA, linked by the datasphere.
Hyperion by Dan Simmons, 1989Set in 2851On track825 years left to climb 6 TRL steps (137.5 yrs/step)

Closest todayLanguage models that imitate historical writers from their texts, and teleoperated humanoid robots; growing an adult body or controlling one remotely is not possible.

Dependency stack

Research TRL 1–3Development TRL 4–6Deployment TRL 7–9
Sort by
  • The persona must think and act as a full person, not a chatbot
    ✕3 blockers›
    • Reliability collapses on tasks longer than a few hours at high success thresholds
    • No persistent learning from experience after deployment
    • Weak grounding in physical and social context outside text and code
    TRL 3
  • Running a body remotely needs full motor output and sensory input over a neural link
    ✕4 blockers›
    • Simultaneous stimulation and recording on the same tissue; stimulation artifact swamps spikes
    • Coverage; immersive vision alone implies millions of controllable sites across V1
    • Suppressing the real senses so the artificial stream is not in conflict with them
    • Total implant power and heat once millions of channels are driven
    plausibleTRL 3
  • majorFull-term ectogenesisbottleneck
    The body has to be gestated and grown without a surrogate mother
    • The gap between day-14 embryo culture and artificial-placenta viability covers organogenesis, the hardest and least substitutable phase
    • No artificial implantation or placental organ exists to supply hormones and nutrient exchange during that gap
    • Scaling implies thousands of parallel units with sterility and uninterrupted power for nine months each
    TRL 2
    • The early half cannot be built without reconstructing implantation and placental exchange
      ✕3 blockers›
      • The placenta's endocrine and nutrient-exchange functions have not been reproduced by any device or culture
      • Maternal immune tolerance at the interface is not understood well enough to substitute for
      • Human implantation cannot be studied past the 14-day limit, so the critical window is inaccessible
      TRL 3
    • An engineered placenta is a vascularized tissue that must be grown, not just machined
      ✕4 blockers›
      • Capillary-scale perfusion cannot be printed and must self-assemble, which is uncontrolled today
      • Printed tissue must mature into function (filtration, metabolism, contraction), and maturation protocols stall at fetal-like performance
      • Cell demand of 10^10-10^11 per organ exceeds current manufacturing
      • Mechanical integration - ureters, bile ducts, valves - has no demonstrated fabrication route
      TRL 4
      • Without a capillary network, tissue thicker than a few hundred microns dies
        ✕3 blockers›
        • Printing resolution stops at tens of microns while capillaries are 5-10 microns, so the smallest and most numerous vessels must self-assemble
        • Engineered endothelium is thrombogenic, so perfused constructs clot
        • No method guides anastomosis of a construct's vasculature to host vessels at scale
        TRL 3
      • Banked-cell organs are not patient-matched, so acceptance must be engineered
        ✕3 blockers›
        • Chronic antibody-mediated rejection proceeds even under current immunosuppression
        • Tolerance protocols trade rejection risk for conditioning toxicity and graft-versus-host disease
        • No assay predicts which recipients can be safely weaned off drugs
        TRL 5
      • One organ needs 10^10-10^11 clinical-grade cells of several types
        ✕3 blockers›
        • Genomic instability and drift accumulate over the expansion needed for 10^11 cells
        • Each organ needs many cell types differentiated on a synchronized schedule, not one lineage
        • Cost per cell at current media and reagent prices makes a printed organ unaffordable
        TRL 6
    • Supplies the late-gestation half of the problem
      ✕4 blockers›
      • Miniaturization - the lamb model weighs 1-3 kg while a 23-week human fetus is about 500 g, with shorter umbilical cannulation distances
      • Umbilical vessel vasospasm and thrombosis during cannulation and over weeks of support
      • Infection control in a continuously exchanged sterile fluid environment
      • No agreed proof-of-concept endpoint or animal model that maps onto human neonatal outcomes
      TRL 5
      • Sterile fluid exchange, nutrition and waste handling must run continuously without interruption
        ✕2 blockers›
        • Food production closure
        • Microbial and ecological stability over years
        TRL 5
      • Gas exchange through the umbilical circuit for weeks is the core function
        ✕3 blockers›
        • Blood-surface contact activates coagulation, so runs depend on anticoagulation that causes bleeding in fragile patients
        • Oxygenator plasma leakage and fiber fouling limit single-circuit life
        • Hemolysis and platelet consumption scale with pump shear and circuit length
        TRL 7
  • Cloning a body from recovered DNA
    ✕3 blockers›
    • Incomplete epigenetic reprogramming of the donor nucleus produces placental defects and large-offspring syndrome
    • Efficiency is a few percent of transferred embryos, so each live birth consumes many donor eggs and surrogates
    • Donor egg supply is the limiting input for any primate-scale program
    TRL 5
  • Reconstructing a voice and style from a person's writings is the part current models already do
    TRL 7

Who could unlock it

Full-term ectogenesisTRL 2bottleneck
  • Jacob HannaResearcher, Weizmann Institute of Science
    Grew natural mouse embryos ex utero from E5.5 to E11 through organogenesis (Nature, 2021) and generated transgene-free post-gastrulation whole embryo models from naive stem cells (Cell Stem Cell, 2025); holds an ERC grant titled ExUteroEmbryogenesis
  • Alejandro Aguilera-CastrejonResearcher, Janelia Research Campus, HHMI
    Built the roller and perfusion ex utero culture platform in the Hanna lab and now works explicitly toward birthing a mouse from an incubator
  • Renewal BioStartup
    Israeli company co-founded by Hanna in 2022 that licensed the Weizmann ex utero and synthetic-embryo patents (about $9M raised via NFX) to grow early tissue as a cell source
  • Vitara BiomedicalStartup
    Working the opposite end of the same problem - fluid-filled support from roughly 22 weeks of human gestation onward, the only part of full-term ectogenesis anywhere near clinical use
Artificial general intelligenceTRL 3
  • OpenAIStartup
    Building Stargate with Oracle, SoftBank and MGX, with ~7 GW planned by Sept 2025 toward 10 GW by 2028; states AGI as its mission
  • Google DeepMindCompany
    Released Gemini 3 (Dec 2025); Demis Hassabis frames AGI as the lab's goal
  • AnthropicStartup
    Claude models led METR long-task time-horizon measurements in 2025-2026
  • Demis HassabisResearcher, Google DeepMind
    Google DeepMind CEO and 2024 Nobel laureate (AlphaFold); directs Gemini and the lab's AGI research
Full-sensorium bidirectional brain-computer interfaceTRL 3
  • Robert GauntResearcher, University of Pittsburgh Rehab Neural Engineering Labs
    Leads the Pittsburgh ICMS program that showed biomimetic stimulation produces more natural touch in humans (J. Neural Eng. 2025)
  • Eduardo FernándezResearcher, Miguel Hernández University of Elche
    Implanted 96-channel arrays in visual cortex of blind volunteers who recognised letters and shapes (JCI 2021)
  • NeuralinkStartup
    Raised $650M Series E in 2025; has human motor-BCI participants and FDA Breakthrough designations for vision and speech restoration
  • ParadromicsStartup
    First long-term Connexus implant in June 2026; participant used it for real-time speech, with sensory feedback on the roadmap
Somatic cell nuclear transfer cloningTRL 5
  • Qiang SunResearcher, Institute of Neuroscience, Chinese Academy of Sciences
    Cloned the macaques Zhong Zhong and Hua Hua (2018) and ReTro, the first cloned rhesus to reach adulthood, using trophoblast replacement (2024)
  • Institute of Neuroscience, Chinese Academy of SciencesGovernment lab
    The only group to have produced primate clones; its 2024 result consumed 113 transferred embryos for one surviving animal
  • ViaGen Pets and EquineCompany
    The commercial SCNT operation, cloning cats, dogs and horses and the Przewalski's horse Kurt; acquired by Colossal Biosciences in November 2025
  • Colossal BiosciencesStartup
    Uses cloning from edited cell lines as its route to live animals and bought ViaGen in 2025 to bring that throughput in-house

Beyond engineering

  • Personhood and rights of a cloned body with no native mind
  • Consent and estate rights over reconstructing a dead person